CynthiaCBrinsonMD

PubMed

• 86 citations
  Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 resul...
  David A. Wohl, Yazdan Yazdanpanah, Axel Baumgarten, Amanda Clarke, Melanie A. Thompson, Cynthia Brinson, Debbie Hagins, Moti Ramgopal, Andrea Antinori, Xuelian Wei, Ri...> ;The Lancet. HIV. 2019 Jun 1
• 34 citations
  Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, F...
  Debbie Hagins, Chloe Orkin, Eric S. Daar, Anthony Mills, Cynthia Brinson, Edwin DeJesus, Frank A. Post, Morales-Ramirez J, Melanie A. Thompson, Olayemi Osiyemi, B. Ras...> ;HIV Medicine. 2018 Aug 12
• 5 citations
  Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide.
  Paul E. Sax, Edwin DeJesus, Gordon Crofoot, Douglas J. Ward, Paul Benson, Robin Dretler, Anthony Mills, Cynthia Brinson, Xuelian Wei, Sean E Collins, Andrew T. A. Cheng> ;AIDS. 2018 Jul 31
• 89 citations
  Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HI...
  Molina, J. M., Molina, J. M., Molina, J. M., Molina, J. M., Ward, D., Ward, D., Ward, D., Ward, D., Brar, I., Brar, I., Brar, I., Brar, I., Mills, A., Mills, A., Mills...> ;The lancet. HIV. 2018 Jun 22
• 252 citations
  Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiorit...
  Josep M. Llibre, Chien-Ching Hung, Cynthia Brinson, Francesco Castelli, Pierre-Marie Girard, Lesley P Kahl, Elizabeth A. Blair, Kostas Angelis, Brian Wynne, Kati Vande...> ;Lancet. 2018 Mar 3
• 84 citations
  Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United St...
  Deanna Kerrigan, Andrea Mantsios, Miguel Górgolas, María Luisa Montes, Federico Pulido, Cynthia Brinson, Jerome deVente, Gary Richmond, Sarah W. Beckham, Paige Hammond...> ;Plos One. 2018 Jan 5
• Dolutegravir/abacavir/lamivudine Versus Current ART in Virally Suppressed Patients (STRIIVING): A 48-Week, Randomized, Non-Inferiority, Open-Label, Phase IIIb Study
  Jordan E Lake, Lizette Santiago, Justin A Koteff, Cynthia Brinson> ;Antiviral Therapy.
• 44 citations
  Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfecte...
  Joel E. Gallant, Jason Brunetta, Gordon Crofoot, Paul Benson, Anthony Mills, Cynthia Brinson, Shinichi Oka, Andrew K. Cheng, Will Garner, Marshall W. Fordyce, Moupali ...> ;Journal of Acquired Immune Deficiency Syndromes. 2016 Nov 1
• Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and...
  Wohl D, Oka S, Clumeck N, Clarke A, Brinson C, Stephens J, Tashima K, Arribas JR, Rashbaum B, Cheret A, Brunetta J, Mussini C, Tebas P, Sax PE, Cheng A, Zhong L, Calle...> ;J. Acquir. Immune Defic. Syndr.. 2016-05-01
• 126 citations
  Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment ...
  Gallant, J. E., Gallant, J. E., Gallant, J. E., Daar, E. S., Daar, E. S., Daar, E. S., Raffi, F., Raffi, F., Raffi, F., Brinson, C., Brinson, C., Brinson, C., Ruane, P...> ;The lancet. HIV. 2016 Apr 3
• 45 citations
  Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised cont...
  Lalezari, J. P., Latiff, G. H., Brinson, C., Echevarría, J., Treviño-Pérez, S., Bogner, J. R., Thompson, M., Fourie, J., Sussmann Pena, O. A., Mendo Urbina, F. C., ...> ;The lancet. HIV. 2015 Oct 2
• 144 citations
  Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1...
  David A. Margolis, Cynthia Brinson, Graham H R Smith, Jerome De Vente, Debbie Hagins, Joseph J. Eron, Sandy Griffith, Marty St. Clair, Marita Stevens, Peter Williams, ...> ;The Lancet. Infectious Diseases. 2015 Oct 1
• 49 citations
  Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials
  F Raffi, Anita Rachlis, Cynthia Brinson, Keikawus Arastéh, Miguel Górgolas, Clare A. Brennan, Keith A. Pappa, Steve Almond, Catherine Granier, W. Garrett Nichols, Robe...> ;AIDS. 2015 Jan 14
• 2 citations
  Safety profile of HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 analysis.
  Jacob Lalezari, Gulam H Latiff, Cynthia Brinson, Juan Echevarria, Sandra Treviño-Pérez, Johannes R. Bogner, David A. Stock, Samit R Joshi, George J. Hanna, Max Lataillade> ;Journal of the International AIDS Society. 2014 Nov 2
• 3 citations
  HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 sub-group analysis.
  Cynthia Brinson, Jacob Lalezari, Latiff H Gulam, Melanie Thompson, Juan Echevarria, Sandra Treviño-Pérez, David A. Stock, Joshi R Samit, Hanna J George, Max Lataillade> ;Journal of the International AIDS Society. 2014 Feb 11
• 54 citations
  Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subjects.
  Jacob Lalezari, Joseph Gathe, Cynthia Brinson, Melanie Thompson, Calvin J. Cohen, Edwin DeJesus, Jorge Galindez, Jerome A. Ernst, David E. Martin, Sandra M. Palleja> ;Journal of Acquired Immune Deficiency Syndromes. 2011 Jun 1
• Join now to see all